Aldagen is a wholly-owned subsidiary of Cytomedix, Inc (BB:CMXI). The Aldagen subsidiary develops proprietary regenerative cell therapies in the vascular area. These cell therapeutics consist of a specific population of stem cells from a patient’s own bone marrow. Aldagen isolates these cells, which are typically less than 1% of all cells in bone marrow, using our proprietary technology. Based on preclinical studies and our clinical trials to date, Aldagen believes these cell populations have the potential to promote the regeneration of multiple types of cells and tissues, including the growth of new blood vessels, a process known as angiogenesis. Aldagen's product candidates are ALD-301 for the treatment of critical limb ischemia, ALD-201 for the treatment of ischemic heart failure and ALD-401 for the treatment of ischemic stroke.
Company Details
- Founded
- -
- Phone
- 919-484-2571
- in****@****gen.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- aldagen.com
- Keywords
- Stem cell therapeutics.
Aldagen, Inc Questions
Aldagen, Inc's helpline number is 919-484-2571
Aldagen, Inc's website is aldagen.com
Aldagen, Inc's LinkedIn profile is https://www.linkedin.com/company/aldagen-inc
Aldagen, Inc's industry is
Biotechnology Research
Aldagen, Inc's top competitors are
American Honors,
Fishtree,
Appfluent Technology,
Gemoab Gmbh,
Authntkt,
Biorbyt,
Achelios Therapeutics,
Cognosci Inc.,
Fishtree - Now A Follett Company!,
Calvert Education.
Aldagen, Inc's support email address is info@aldagen.com
Aldagen, Inc's categories are Biotechnology Research
Aldagen, Inc's founding year is 2001
